title: Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine.
authors.affiliation: Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: V
authors.initials: V
authors.lastname: Visconte
authors.affiliation: Division of Hematology/Oncology, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
authors.forename: S T
authors.initials: ST
authors.lastname: Nawrocki
authors.affiliation: Division of Hematology/Oncology, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Espitia
authors.affiliation: USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
authors.forename: K R
authors.initials: KR
authors.lastname: Kelly
authors.affiliation: Cell Signaling Technology, Danvers, MA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Possemato
authors.affiliation: Cell Signaling Technology, Danvers, MA, USA.
authors.forename: S A
authors.initials: SA
authors.lastname: Beausoleil
authors.affiliation: Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Han
authors.affiliation: Leukemia Program, Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: H E
authors.initials: HE
authors.lastname: Carraway
authors.affiliation: Leukemia Program, Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: A
authors.initials: A
authors.lastname: Nazha
authors.affiliation: Leukemia Program, Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Advani
authors.affiliation: Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: J P
authors.initials: JP
authors.lastname: Maciejewski
authors.affiliation: Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.|Leukemia Program, Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Sekeres
authors.affiliation: Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Carew
mesh_terms: D001374:Azacitidine / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D003517:Cyclopentanes / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism* / Q000473:pathology; D009363:Neoplasm Proteins / Q000378:metabolism*; D040901:Proteomics; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D003517:Cyclopentanes; D009363:Neoplasm Proteins; D011743:Pyrimidines; D001374:Azacitidine; C539933:pevonedistat